Can Non-Pharmacological Treatment Promote Additional Benefit for Children with Familial Hypercholesterolemia Treated with Statins?
Familial hypercholesterolemia (FH) is described as an autosomal dominant hereditary disease characterized by elevation of total cholesterol and low density lipoprotein (LDL-c).
FH is considered a major modifiable risk factor for the development of atherosclerosis and cardiovascular disease (CVD). The early institution of lipid-lowering therapy and its lifelong maintenance are important aspects in the prevention of premature CVD and the risk of death in this population, increasing life expectancy in these patients.
[…]
Comments are moderated by the editorial team before publication. Discussions should be evidence-based and use scientific language. Conflicts of interest should be declared.